Biocorrx (OTCMKTS:BICX) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.
This is a breakdown of current recommendations for Biocorrx and IMAC, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares Biocorrx and IMAC’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|IMAC||$6.70 million||2.06||-$3.05 million||N/A||N/A|
IMAC has higher revenue and earnings than Biocorrx.
Institutional & Insider Ownership
0.6% of IMAC shares are held by institutional investors. 21.4% of Biocorrx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Biocorrx and IMAC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
IMAC beats Biocorrx on 5 of the 8 factors compared between the two stocks.
Biocorrx Company Profile
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. It offers treatment philosophy that combines medical intervention and a proprietary cognitive behavioral therapy program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. It also engages in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. The company was founded by Neil Terrence Muller and George O’Neill on January 28, 2008 and is headquartered in Anaheim, CA.
IMAC Company Profile
IMAC Holdings, Inc. operates a chain of integrated medicine and chiropractic regeneration centers. The company's outpatient clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. As of September 17, 2018, it had 11 clinics, including 6 owned and 5 managed clinics in Kentucky, Missouri, and Tennessee, the United States. The company was founded in 2000 and is based in Brentwood, Tennessee.
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.